

CLAIMS

1. A modified IgG comprising: a feline IgG constant domain comprising at least one amino acid substitution relative to a wild-type feline IgG constant domain, wherein said substitution is at amino acid residue 428 or 434, numbered according to the EU index as in Kabat.
2. The modified IgG of claim 1, wherein said substitution is a substitution of serine at position 428 with leucine (S428L).
3. The modified IgG of claim 1, wherein said substitution is a substitution of serine at position 434 with histidine (S434H).
4. The modified IgG of claim 1, wherein said feline IgG constant domain comprises two amino acid substitutions, wherein the first substitution is at amino acid residue 428 and the second substitution is at amino acid residue 434.
5. The modified IgG of claim 4, wherein the first substitution is a substitution of serine at position 428 with leucine (S428L) and the second substitution is a substitution of serine at position 434 with histidine (S434H).
6. The modified IgG of claim 1, wherein the modified IgG has a higher affinity for FcRn than the IgG having the wild-type feline IgG constant domain.
7. The modified IgG of claim 1, wherein the modified IgG is a feline or felinized IgG.
8. The modified IgG of claim 1, wherein the IgG constant domain comprises an Fc constant region having CH2 or CH3 domain, or a combination thereof.
9. The modified IgG of claim 1, wherein the IgG constant domain comprises the amino acid sequence set forth in SEQ ID NO.: 1 or 2.
10. A pharmaceutical composition comprising the modified IgG of any one of claims 1-9 and a pharmaceutically acceptable carrier.

11. A kit comprising the modified IgG of any one of claims 1-9, in a container, and instructions for use.
12. A polypeptide comprising the modified IgG of any one of claims 1-9.
13. An immunoglobulin comprising the modified IgG of any one of claims 1-9.
14. A vector comprising the nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO.: 1 or 2.
15. An isolated cell comprising the vector of claim 14.
16. A method of manufacturing an antibody or a molecule, the method comprising: providing the cell of claim 15; and culturing said cell.
17. Use of an immunoglobulin for increasing its serum half-life in a cat, wherein said immunoglobulin is the immunoglobulin of claim 13.
18. A fusion molecule comprising the modified IgG of any one of claims 1-9.
19. The immunoglobulin of claim 13, wherein said immunoglobulin is an anti-IL31 or anti-NGF molecule.
20. The use of claim 17, wherein said immunoglobulin is an anti-IL31 or anti-NGF molecule.